SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co - Ordinary Shares - Class A

ASPC is trending amidst intense short squeeze speculation, driven by its extremely low float and reports of high borrow rates. The community is actively discussing massive price targets and frequent trading halts, drawing comparisons to other recent low-float runners while also noting caution around its status as a Chinese SPAC.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is experiencing a massive rally driven by reports of intensifying physical silver shortages, especially with China's impending export restrictions, leading to significant price discrepancies between Eastern and Western markets. This has ignited heated debate among investors, with many celebrating an end to decades of price suppression and anticipating triple-digit valuations, while others caution about an unsustainable bubble and an imminent reversal. The surge is underpinned by strong industrial demand from AI and EV sectors, combined with a broader flight to tangible assets amidst geopolitical uncertainties.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing a powerful surge to fresh record highs, driven by intensifying geopolitical tensions, ongoing concerns about currency debasement, and widespread expectations for future policy easing. The community is actively debating whether this rally signifies a fundamental shift towards tangible assets amid a weakening dollar and massive government spending, or if it's an overextended move poised for a sharp correction, particularly with many noting gold's outperformance relative to other asset classes.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

Universe Pharmaceuticals (UPC) is drawing significant attention due to its extremely low share float, with the community actively anticipating a potential short squeeze and setting ambitious price targets. Many traders are highlighting the company's substantial cash reserves as a key factor contributing to its perceived undervaluation, while some express caution, warning of potential 'pump and dump' dynamics often seen in similar low-float Chinese stocks.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space Inc. ($FJET) is experiencing extreme volatility and trending due to an exceptionally high borrow rate, sparking a heated short squeeze discussion. While proponents highlight its low float and unique Mach 2 aerospace technology with potential government contracts, critics point to significant dilution, lack of revenue, and classify it as a speculative 'pump and dump' within the currently active space sector.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is heavily trending amid China's recent sanctions against the company, which many in the community interpret as a significant validation of its role as a critical U.S. defense contractor. This sentiment is amplified by the U.S. government's push to ban foreign-made drones, creating a clear market opportunity for Red Cat's Blue UAS-compliant platforms and anticipated large defense budgets for U.S.-manufactured small drones and unmanned surface vessels. Despite recent price fluctuations, discussion centers on the company's preparedness to meet increased demand through domestic production, fueling expectations for substantial contract awards.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is driving intense market conversation due to its compute-in-memory APU chips, specifically the Gemini-II, following recent revenue growth, substantial equity financing, and a strategic focus on the expanding drone and defense edge AI sectors. Bulls are emphasizing the chip's purported energy efficiency and academic validation as a disruptive solution for specialized applications, often drawing comparisons to traditional GPUs. However, a vocal skeptical contingent questions the technology's commercial track record, citing a history of minimal APU sales and potential technical limitations, with all eyes on eagerly awaited Gemini-II benchmark results.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending after releasing preliminary data from its FLAMINGO-01 trial, showing an impressive estimated 80% reduction in breast cancer recurrence rates for patients receiving its GLSI-100 immunotherapy. This positive update, coupled with soaring cost-to-borrow rates and high short interest, has fueled intense community discussion about a potential short squeeze and the stock's significant undervaluation, with many anticipating a major partnership or buyout given its impact on breast cancer treatment.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending as geopolitical tensions amplify the urgent demand for domestic critical minerals. The community is actively discussing UAMY's unique position as a leading supplier of military-grade antimony, fueled by expectations of significant government contracts and a major capacity expansion nearing completion. This focus on securing strategic supply chains underscores the company's potential for continued momentum in the sector.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp (OMER) is trending due to the recent FDA approval of its pioneering drug Yartemlea for transplant-associated thrombotic microangiopathy (TA-TMA), making it the first and only approved treatment for this life-threatening condition across adult and pediatric patients. This significant catalyst, combined with a major licensing deal and a strengthened balance sheet, is fueling widespread bullish sentiment and discussions around substantial upside potential, including a potential short squeeze. The community eagerly anticipates further details on commercialization and pricing from an upcoming conference call.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Squarepoint Ops LLC Takes $1.27 Million Position in Prothena Corporation plc $PRTA

Squarepoint Ops LLC purchased a new stake in shares of Prothena Corporation plc (NASDAQ:PRTA - Free Report) during the 2nd quarter, according to the company in its most recent filing with the...

Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Analysts

Shares of Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) have earned an average rating of "Hold" from the twelve research firms that are presently covering the stock, Marketbeat Ratings...

Birchview Capital LP Has $2.74 Million Stock Holdings in Prothena Corporation plc $PRTA

Birchview Capital LP boosted its position in shares of Prothena Corporation plc (NASDAQ:PRTA - Free Report) by 35.5% in the second quarter, according to its most recent Form 13F filing with the...

Prothena Announces Board of Directors Update

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...

Prothena Corporation plc $PRTA Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. grew its holdings in Prothena Corporation plc (NASDAQ:PRTA - Free Report) by 116.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and...

Prothena (NASDAQ:PRTA) Stock Price Up 7.4% - Here's Why

Prothena (NASDAQ:PRTA) Trading Up 7.4% - What's Next...

Citizens Jmp Forecasts Strong Price Appreciation for Prothena (NASDAQ:PRTA) Stock

Citizens Jmp upped their price target on Prothena from $11.00 to $19.00 and gave the company a "market outperform" rating in a report on Monday...

Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Brokerages

Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) has received a consensus rating of "Hold" from the ten analysts that are currently covering the firm, Marketbeat Ratings reports. Two...

Prothena Corporation plc $PRTA Position Lessened by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. decreased its position in shares of Prothena Corporation plc (NASDAQ:PRTA - Free Report) by 79.3% in the second quarter, according to the company in its...

Prothena Announces Poster Presentation on its TDP-43 CYTOPE Program at Neuroscience 2025

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced a...

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Current Price	$9.51
Prev Close	$9.69
Open	$9.66
Dividend Yield	0.00%
50-Day Moving Average	$10.25
Beta	1.05
Avg. Volume	583,738.63
PE Ratio	-1.86

52-Week High	$16.67
52-Week Low	$4.32
Market Capitalization	$521.61M
EPS (Annual)	-$2.27
Price to Book	1.77
Revenue Per Employee	$829,184.05
Enterprise Value/EBITDA	N/A

PRTA
Prothena Corporation plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PRTA News

PRTAProthena Corporation plc